Glaukos Announces Participation in Wells Fargo Healthcare Conference
23 August 2018 - 6:15AM
Business Wire
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical
technology and pharmaceutical company focused on the development
and commercialization of novel surgical devices and sustained
pharmaceutical therapies designed to transform the treatment of
glaucoma, today announced that its management is scheduled to
participate in the Wells Fargo Healthcare Conference on Wednesday,
September 5, 2018, at 1:15 p.m. EDT in Boston, MA.
A live audio webcast for this event will be available in the
Investors section of the Glaukos website at
http://investors.glaukos.com and will be archived for 90 days.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology
and pharmaceutical company focused on the development and
commercialization of novel surgical devices and sustained
pharmaceutical therapies designed to transform the treatment of
glaucoma, one of the world’s leading causes of blindness. The
company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to
revolutionize the traditional glaucoma treatment and management
paradigm. Glaukos launched the iStent®, its first MIGS device, in
the United States in July 2012 and is leveraging its platform
technology to build a comprehensive and proprietary portfolio of
micro-scale injectable therapies designed to address the complete
range of glaucoma disease states and progression. The company
believes the iStent inject®, measuring 0.36 mm long and 0.23 mm
wide, is the smallest medical device ever approved by the FDA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180822005489/en/
Glaukos CorporationChris Lewis, 949-481-0510Director, Investor
Relations, Corporate Strategy &
Developmentclewis@glaukos.com
Glaukos (NYSE:GKOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Glaukos (NYSE:GKOS)
Historical Stock Chart
From Apr 2023 to Apr 2024